Cancer - Side effect drugs Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cancer - Side effect drugs

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John McCarthy who started this subject	5/18/2002 7:42:48 PM
From: John McCarthy	of 57

[2002]-[ONT-093]-[oral P-gp inhibitor][Biospace] Ontogen Corporation is a drug discovery and development company focused on the advancement of proprietary small molecule therapeutic agents to address unmet medical needs in cancer, infectious diseases and other chronic medical conditions. Ontogen's strengths in chemistry, technology, engineering and biology have yielded eight active development programs. These strengths are exemplified by the company's developmental-stage therapeutic candidate, ONT-093, a P-glycoprotein (P-gp) inhibitor, which progressed from discovery to clinical evaluation in less than 18 months. The drug is expected to have utility in several applications: * Inhibition of P-gp in tumors for the prevention and reversal of multidrug resistance associated with cancer chemotherapy (Phase I) * Inhibition of P-gp in the intestine to enhance oral bioavailability of drugs that are P-gp substrates requiring either high dosage forms or i.v. administration (Phase I) * Inhibition of P-gp at the blood brain barrier to increase central nervous system (CNS) penetration of drugs that are P-gp substrates (pre-clinical) biospace.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next